Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT02914522 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02914522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02914522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
November 14, 2016
Completion date
March 31, 2020
Enrollment
1,351 (actual)
Sites
343

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis